High Dose Ascorbic Acid for Plasma Cell Disorders
NCT03602235
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This is a research study where doctors will test whether a combination of medicine called low dose melphalan and high dose ascorbate acid is safe and helps people who have a kind of cancer called multiple myeloma that has come back after treatment. The doctors will closely watch the patients to see if they have any side effects from the medicine, and also see if the medicine helps to improve their health.
This is a research study where doctors will test whether a combination of medicine called low dose melphalan and high dose ascorbate acid is safe and helps people who have a kind of cancer called multiple myeloma that has come back after treatment. The doctors will closely watch the patients to see if they have any side effects from the medicine, and also see if the medicine helps to improve their health.
Third Opinion AI Generated Synopsis
Trial Summary
This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.
This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
